Arrowhead Pharmaceuticals, Inc. (ARWR) Plozasiran sNDA Accepted Into FDA STAR Program
Arrowhead Pharmaceuticals (ARWR) announced FDA acceptance of plozasiran into the STAR program for its severe hypertriglyceridemia sNDA, enabling Priority Review without using a PRV. The company must submit the sNDA by year-end 2026.
How this was made
The 30-second read
Why it matters
Regulatory acceleration can materially affect valuation ahead of the formal sNDA submission.
Market read
First‑time FDA STAR acceptance is a catalyst for ARWR and may influence sector sentiment.
What to watch
Potential competition in severe hypertriglyceridemia space and reimbursement uncertainties.
Background
Arrowhead Pharmaceuticals is developing plozasiran for severe hypertriglyceridemia; the STAR program provides a fast‑track pathway.
Ticker impact
FDA accepted Arrowhead's plozasiran sNDA into the STAR program, enabling Priority Review.
likely upside as market prices in potential priority review and expedited approval.
First report of STAR entry; biotech stocks typically rally on FDA fast‑track designations.
Market effects
May lift other gene‑therapy and RNA‑based biotech peers as FDA signals willingness to expedite similar programs.
US biotech sector could see modest gains on the news.
Limited to investors focused on US biotech pipelines.
Counterpoint
If the sNDA fails to meet the PDUFA deadline, the initial enthusiasm could reverse.
Key entities
- CompanyArrowhead Pharmaceuticals
US‑listed biotech developing RNA‑based therapies.
